Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients.

Constance Chapuis-BironAnne BourrierMaria NachuryStéphane NanceyYoram BouhnikMélanie SerreroLaura Armengol-DebeirAnthony BuissonMy-Linh Tran-MinhCamille ZallotMathurin Fumery Guillaume BouguenVered AbitbolStéphanie ViennotElise ChanteloupSylvie RajcaNina DibAnne-Laure ParmentierLaurent Peyrin Biroulet Lucine Vuittonnull null

Published in: Alimentary pharmacology & therapeutics (2020)

We identified a low rate of success of vedolizumab in patients with active perianal Crohn's disease, and nearly one third of patients with inactive perianal Crohn's disease had perianal recurrence. Further evaluation is warranted in prospective studies.

Keyphrases

end stage renal disease
hidradenitis suppurativa
newly diagnosed
ejection fraction
chronic kidney disease
clinical trial
randomized controlled trial
peritoneal dialysis
patient reported outcomes
case control
patient reported
free survival